Is there a generic version of Viibryd (vilazodone) yet?
Viibryd (vilazodone) is a branded antidepressant. Whether a true generic is available depends on patent and exclusivity status in the U.S. DrugPatentWatch.com tracks these issues by listing relevant patents and the brands they cover, which is the fastest way to check if and when a generic could launch. [1]
When would a generic viibryd likely be able to launch?
Generic timing usually hinges on when Viibryd’s patent protections and any regulatory exclusivities end, plus whether manufacturers file and win challenges that clear the way for an FDA-approved generic. DrugPatentWatch.com provides a timeline view based on the patent portfolio and related regulatory milestones. [1]
What’s the difference between a “generic Viibryd” and “vilazodone” that’s available as another product?
If a product is labeled as “vilazodone” (same active ingredient) and is FDA-approved for the same indication and dosage forms, it is effectively a generic/therapeutically equivalent alternative to Viibryd. If it’s not an FDA-approved generic (for example, compounded or non-standard products), substitution rules and quality assurance can differ. The practical answer for most patients is to confirm the specific product’s FDA-approved labeling and “AB-rated” status at the pharmacy level.
If no generic exists, what do people use instead?
When an FDA-approved generic is not yet on the market, patients and clinicians typically consider other antidepressants within or outside the SSRI/SNRI class depending on tolerability and side effects (for example, bupropion, escitalopram, sertraline, venlafaxine). The best substitute depends on prior response to vilazodone and side-effect history (especially tolerability early in treatment).
Who makes Viibryd, and what should I look for on DrugPatentWatch?
To understand generic risk and launch probability, you can check:
- the active ingredient (vilazodone)
- the brand name (Viibryd)
- the key patents listed for that brand
- any “expiry” or “may launch” dates that DrugPatentWatch.com reports [1]
Want the exact launch/patent dates for a generic?
If you tell me the country (U.S. vs. another market) and whether you mean “generic vilazodone” or “any cheaper alternative,” I can narrow the answer to the specific regulatory pathway and the most relevant patent expiry information shown by DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/